| Benchmarking the transcriptomic predictive biomarkers for immunotherapy plus chemotherapy: Results from phase III RATIONALE-309 and ORIENT-11 randomized trials. K Chen, A Li, K Xiong, H Zhou, Q Zhang, Y Huang, Z Yan, K Wu, J Zhan, ... Journal of Clinical Oncology 42 (16_suppl), e14624-e14624, 2024 | | 2024 |
| Phase 1b trial of anti‐HER2 antibody inetetamab and pan‐HER inhibitor pyrotinib in HER2‐positive advanced lung cancer Y Huang, Y Zhao, Y Huang, Y Yang, Y Zhang, S Hong, H Zhao, S Zhao, ... MedComm 5 (5), e536, 2024 | | 2024 |
| Abstract LB266: AMG510-mediated inactivation of BCL-xL protein promotes Gasdermin-E-dependent pyroptosis in KRAS-G12C mutant non-small cell lung cancer L Luo, A Li, W Du, M Chen, JI Li, Y Zhou, L Zhang, S Hong Cancer Research 84 (7_Supplement), LB266-LB266, 2024 | | 2024 |
| Neoadjuvant-Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients With Resectable NSCLC: An Indirect Meta-Analysis Y Zhou, A Li, H Yu, Y Wang, X Zhang, H Qiu, W Du, L Luo, S Fu, L Zhang, ... JAMA Network Open 7 (3), e241285-e241285, 2024 | 1 | 2024 |
| Pretreatment serum lactate dehydrogenase and metastases numbers as potential determinants of anti-PD-1 therapy outcome in nasopharyngeal carcinoma WAS Ali, X Huang, Y Wu, Y Ma, H Pan, J Liao, Z Yang, S Hong, Y Yang, ... Cancer Control 30, 10732748221148912, 2023 | 2 | 2023 |
| Impact of prophylactic dexamethasone on the efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy in patients with advanced Non-Squamous Non-Small-Cell lung … H Yu, J Chen, Y Zhou, J Sheng, X Zhang, L He, L Chen, Q Chu, L Zhang, ... International Immunopharmacology 125, 111138, 2023 | 2 | 2023 |
| STK11/LKB1-deficient phenotype rather than mutation diminishes immunotherapy efficacy and represents STING/type I interferon/CD8+ T-cell dysfunction in NSCLC A Li, Y Wang, Z Yu, Z Tan, L He, S Fu, M Shi, W Du, L Luo, Z Li, J Liu, ... Journal of Thoracic Oncology 18 (12), 1714-1730, 2023 | 6 | 2023 |
| STK11/LKB1 and Immune Phenotypes Co-Determine Immunotherapy Outcomes A Li, Y Yang, L Zhang, S Hong Journal of Thoracic Oncology 18 (11), e135-e138, 2023 | | 2023 |
| Tumor response assessment by measuring the single largest lesion per organ in advanced non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitor LN He, T Chen, S Fu, Y Jiang, X Zhang, C Chen, W Du, L Luo, A Li, ... Therapeutic Advances in Medical Oncology 15, 17588359231200463, 2023 | 1 | 2023 |
| Deciphering transcriptomic determinants of the divergent link between PD-L1 and immunotherapy efficacy A Li, L Luo, W Du, Z Yu, L He, S Fu, Y Wang, Y Zhou, C Yang, Y Yang, ... NPJ Precision Oncology 7 (1), 87, 2023 | | 2023 |
| Machine learning-based risk model incorporating tumor immune and stromal contexture predicts cancer prognosis and immunotherapy efficacy LN He, H Li, W Du, S Fu, T Chen, X Zhang, C Chen, Y Jiang, Y Wang, ... Iscience 26 (7), 2023 | 1 | 2023 |
| Safety and efficacy of inetetamab in combination with pyrotinib in HER2 mutant patients with non-small cell lung cancer (NSCLC): An open-label, phase Ib trial. W Fang, Y Zhao, Y Huang, Y Zhang, S Hong, Y Huang, H Zhao, Y Yang, ... Journal of Clinical Oncology 41 (16_suppl), 9105-9105, 2023 | 2 | 2023 |
| Continuation of anti-PD-1 therapy plus physician-choice treatment beyond first progression is not associated with clinical benefit in patients with advanced non-small cell lung … Y Wang, S Fu, X Zhang, W Du, L Luo, Y Jiang, Y Zhou, Y Zhao, Y Yang, ... Frontiers in Immunology 14, 1151385, 2023 | 1 | 2023 |
| Retraction Note: p300 promotes proliferation, migration, and invasion via inducing epithelial-mesenchymal transition in non-small cell lung cancer cells X Hou, R Gong, J Zhan, T Zhou, Y Ma, Y Zhao, Y Zhang, G Chen, Z Zhang, ... BMC cancer 23 (1), 386, 2023 | | 2023 |
| [Cuproptosis-related immune gene signature predicts clinical benefits from anti-PD-1/PD-L1 therapy in non-small-cell lung cancer L Luo, A Li, S Fu, W Du, LN He, X Zhang, Y Wang, Y Zhou, Y Yunpeng, ... Immunologic Research 71 (2), 213-228, 2023 | 3 | 2023 |
| Optimizing the tumor shrinkage threshold for evaluating immunotherapy efficacy for advanced non-small-cell lung cancer W Du, C Chen, L Luo, L He, Y Wang, X Zhang, Y Zhou, Z Lin, S Hong Journal of Cancer Research and Clinical Oncology 149 (3), 1103-1113, 2023 | 1 | 2023 |
| LRRC3B and its promoter hypomethylation status predicts response to anti-PD-1 based immunotherapy L Luo, S Fu, W Du, L He, X Zhang, Y Wang, Y Zhou, S Hong Frontiers in Immunology 14, 959868, 2023 | 1 | 2023 |
| Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy LL Pang, JD Gan, YH Huang, J Liao, WT Zhuang, WAS Ali, SD Hong, ... BMC cancer 23 (1), 72, 2023 | 8 | 2023 |
| Adjuvant therapy in completely resected, EGFR-mutant non-small cell lung cancer: a comparative analysis of treatment efficacy between EGFR-TKI and anti-PD-1/PD-L1 immunotherapy Z Li, X Zhang, Y Wang, Z Yu, C Yang, Y Zhou, S Hong Journal for Immunotherapy of Cancer 11 (10), 2023 | 2 | 2023 |
| Early on-treatment tumor growth rate (EOT-TGR) determines treatment outcomes of advanced non-small-cell lung cancer patients treated with programmed cell death protein 1 axis … LN He, S Fu, H Ma, C Chen, X Zhang, H Li, W Du, T Chen, Y Jiang, ... ESMO open 7 (6), 100630, 2022 | 2 | 2022 |
Huaqiang ZhouSun Yat-sen University Cancer Center在 sysucc.org.cn 的电子邮件经过验证
Huaqiang ZhouSun Yat-sen University Cancer Center在 sysucc.org.cn 的电子邮件经过验证
Zhiyong GuoUniversity of Maryland在 umaryland.edu 的电子邮件经过验证